Celsius Control System™

Providing Rapid Induction (4-5慢/hr), Precise Maintenance and Reversal of Therapeutic Hypothermia — Supported by Published Data

The Celsius Control System™ is a proprietary technology platform that has applications in a variety of clinical situations where patient cooling, precise temperature maintenance and rapid or gradual rewarming are indicated.

INNERCOOL prides itself on being the technology leader in the field of therapeutic hypothermia. INNERCOOL is the only hypothermia company to conduct and publish a large, multi-center, prospective, randomized, controlled study (TCAS) showing how quickly its technology cools patients to 33°C, precisely maintains 33°C as a target temperature and rewarms patients back to normothermia.¹

INNERCOOL has also proven in published data that the CCS is able to rapidly and effectively cool awake patients.² This is an imperative product feature in order for a hypothermia technology to be viable in clinical areas such as acute MI and acute ischemic stroke treatment where intubating and paralyzing patients to facilitate cooling is not viable.

To access a comprehensive database of published papers presented on various clinical indications of mild hypothermia, including all of INNERCOOL's published studies, see our Clinical Literature page.

This Man Was Dead
Doctors are reinventing how they treat sudden cardiac arrest, which is fatal 95 percent of the time. A report from the border between life and death.
Newsweek, July 27, 2007 Issue
Click Here for complete article

¹Steinberg et al "Comparison of Endovascular and Surface Cooling During Unruptured Cerebral Aneurysm Repair". Neurosurgery. Aug. 2004. Volume 55, Number 2, pgs. 307-315.

²Guluma et al "A Trial of Therapeutic Hypothermia via Endovascular Approach in Awake Patients with Acute Ischemic Stroke: Methodology". Academic Emergency Medicine. June 9, 2006.